RVMD - Revolution Medicines, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Redwood City,
United States
Type: Equity
RVMD price evolution
RVMD
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $278.74 | $291.46 | $699.18 | |
| Short term investments | $1315 | $1415.11 | $1156.81 | |
| Net receivables | $1.25 | |||
| Inventory | ||||
| Total current assets | $1579.14 | $1624.73 | $1729.2 | $1879.28 |
| Long term investments | ||||
| Property, plant & equipment | $99.15 | $100.59 | $99.89 | $100.01 |
| Goodwill & intangible assets | $71.81 | $72.08 | $72.35 | |
| Total noncurrent assets | $183.71 | $179.16 | $182.42 | |
| Total investments | $1315 | $1415.11 | $1156.81 | |
| Total assets | $1763 | $1808.44 | $1908.36 | $2061.7 |
| Current liabilities | ||||
| Accounts payable | $24.46 | $29.32 | $32.38 | $61.79 |
| Deferred revenue | ||||
| Short long term debt | $8.33 | $8.17 | $7.37 | |
| Total current liabilities | $110.86 | $105.33 | $93.72 | $143.85 |
| Long term debt | $79.08 | $79.86 | $80.58 | |
| Total noncurrent liabilities | $84.26 | $89.17 | $91.66 | |
| Total debt | $87.41 | $88.03 | $87.94 | |
| Total liabilities | $196.69 | $189.59 | $182.9 | $235.51 |
| Shareholders' equity | ||||
| Retained earnings | -$1543.23 | -$1386.94 | -$1253.71 | -$1137.71 |
| Other shareholder equity | -$1.86 | -$1.2 | $0.54 | |
| Total shareholder equity | $1618.85 | $1725.47 | $1826.19 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $699.18 | $163.15 | $110.23 | $105.35 |
| Short term investments | $1156.81 | $483.53 | $468.56 | $336.47 |
| Net receivables | $1.25 | $4.67 | $5.93 | $6.39 |
| Inventory | ||||
| Total current assets | $1879.28 | $660.18 | $589.77 | $454.12 |
| Long term investments | ||||
| Property, plant & equipment | $100.01 | $73.74 | $71.24 | $36.34 |
| Goodwill & intangible assets | $72.35 | $73.42 | $74.48 | $75.55 |
| Total noncurrent assets | $182.42 | $151.75 | $148.22 | $113.28 |
| Total investments | $1156.81 | $483.53 | $468.56 | $336.47 |
| Total assets | $2061.7 | $811.93 | $737.99 | $567.4 |
| Current liabilities | ||||
| Accounts payable | $61.79 | $21.31 | $14.06 | $12.61 |
| Deferred revenue | $4.46 | $18.93 | $20.59 | |
| Short long term debt | $7.37 | $6.77 | $6.21 | $3.67 |
| Total current liabilities | $143.85 | $61.98 | $60.35 | $47.18 |
| Long term debt | $80.58 | $57.43 | $60.42 | $28.99 |
| Total noncurrent liabilities | $91.66 | $64.76 | $75.07 | $45.55 |
| Total debt | $87.94 | $64.2 | $66.63 | $32.66 |
| Total liabilities | $235.51 | $126.74 | $135.42 | $92.72 |
| Shareholders' equity | ||||
| Retained earnings | -$1137.71 | -$701.34 | -$452.64 | -$265.55 |
| Other shareholder equity | $0.54 | -$1.78 | -$0.38 | $0.12 |
| Total shareholder equity | $1826.19 | $685.19 | $602.57 | $474.68 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.74 | |||
| Cost of revenue | ||||
| Gross Profit | $0.74 | |||
| Operating activities | ||||
| Research & development | $134.93 | $118.02 | $148.48 | |
| Selling, general & administrative | $21.71 | $22.84 | $32.24 | |
| Total operating expenses | $175.71 | $156.64 | $140.86 | $180.72 |
| Operating income | -$156.64 | -$140.86 | -$179.98 | |
| Income from continuing operations | ||||
| EBIT | -$133.23 | -$116 | -$160.89 | |
| Income tax expense | $0.34 | |||
| Interest expense | $20.41 | $0.3 | ||
| Net income | ||||
| Net income | -$156.29 | -$133.23 | -$116 | -$161.54 |
| Income (for common shares) | -$133.23 | -$116 | -$161.54 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $11.58 | $35.38 | $29.39 | $42.98 |
| Cost of revenue | ||||
| Gross Profit | $11.58 | $35.38 | $29.39 | $42.98 |
| Operating activities | ||||
| Research & development | $423.14 | $253.07 | $186.95 | $132.25 |
| Selling, general & administrative | $75.62 | $40.59 | $30.45 | $21.43 |
| Total operating expenses | $498.76 | $293.66 | $217.4 | $153.68 |
| Operating income | -$487.19 | -$258.28 | -$188.01 | -$110.7 |
| Income from continuing operations | ||||
| EBIT | -$439.59 | -$249.13 | -$187.08 | -$108.46 |
| Income tax expense | -$3.52 | -$0.42 | -$0.37 | |
| Interest expense | $0.3 | $0.01 | $0.07 | |
| Net income | ||||
| Net income | -$436.37 | -$248.71 | -$187.09 | -$108.16 |
| Income (for common shares) | -$436.37 | -$248.71 | -$187.09 | -$110.38 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$133.23 | -$116 | -$161.54 | |
| Operating activities | ||||
| Depreciation | $2.8 | $2.76 | $2.86 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $19.77 | $16.21 | $25.43 | |
| Total cash flows from operations | -$128.17 | -$160.56 | -$120.56 | |
| Investing activities | ||||
| Capital expenditures | -$2.4 | -$3.17 | -$2.32 | |
| Investments | $110.34 | -$244.8 | -$378.08 | |
| Total cash flows from investing | -$161.49 | $107.94 | -$247.97 | -$380.4 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $7.5 | $0.81 | $2.55 | |
| Net borrowings | ||||
| Total cash flows from financing | $85.61 | $7.5 | $0.81 | $839.35 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$495.03 | -$12.72 | -$407.72 | $338.39 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$436.37 | -$248.71 | -$187.09 | -$108.16 |
| Operating activities | ||||
| Depreciation | $9.31 | $9.66 | $7.33 | $6.54 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $61.77 | $31.2 | $20.72 | $8.89 |
| Total cash flows from operations | -$350.57 | -$224.4 | -$147.18 | -$100.06 |
| Investing activities | ||||
| Capital expenditures | -$7.73 | -$10.82 | -$6.53 | -$2.93 |
| Investments | -$334.87 | -$13.3 | -$135.59 | -$231.3 |
| Total cash flows from investing | -$342.6 | -$24.12 | -$142.12 | -$234.23 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $392.39 | $301.39 | $294.6 | $422.78 |
| Net borrowings | ||||
| Total cash flows from financing | $1229.2 | $301.43 | $294.18 | $422.78 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $536.03 | $52.91 | $4.88 | $88.48 |
News
Fundamentals
| Market cap | $13.22B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 167.75M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$567.06M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -23.30 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.38 |
|---|---|
| ROA | -30.08% |
| ROE | N/A |
| Debt/Equity | 0.13 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 14.24 |
| Quick ratio | N/A |